Nikitin E N, Krasnoperova O V, Nikitin Iu E
Klin Med (Mosk). 2009;87(3):64-7.
The efficiency of therapy with the iron-containing preparation Ferro-Folgamma (Vervag Pharma, Germany) was evaluated in 62 men and women aged from 18 to 82 years with iron-deficiency anemia. Criteria for the efficiency were changes in clinical symptoms of anemia, hemoglobin level, erythrocyte and reticulocyte counts, packed cell volume, erythrocyte indices (mean erythrocyte volume, average content and concentration of hemoglobin in erythrocytes), erythropoietin level, and characteristics of iron metabolism (serum iron and ferritin levels, total iron-binding capacity of the serum, coefficient of ferritin saturation with iron), and drug tolerance. It was shown that Ferro-Folgamma is fairly well tolerated by the patients and produces good therapeutic effect when used to treat and prevent iron-deficiency anemia. Also, the study demonstrated that blood erythropoietin level being a sensitive indicator of hypoxia, it may be used as one of the most important criteria for the assessment of treatment efficiency in patients with iron-deficiency anemia.
对62名年龄在18至82岁之间的缺铁性贫血男性和女性，评估了含铁制剂Ferro - Folgamma（德国Vervag制药公司）的治疗效果。疗效标准包括贫血临床症状的变化、血红蛋白水平、红细胞和网织红细胞计数、血细胞比容、红细胞指数（平均红细胞体积、红细胞内血红蛋白的平均含量和浓度）、促红细胞生成素水平以及铁代谢特征（血清铁和铁蛋白水平、血清总铁结合力、铁蛋白铁饱和度系数），还有药物耐受性。结果表明，患者对Ferro - Folgamma耐受性相当良好，用于治疗和预防缺铁性贫血时产生良好的治疗效果。此外，该研究表明，作为缺氧敏感指标的血促红细胞生成素水平，可作为评估缺铁性贫血患者治疗效果的最重要标准之一。
